Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-400 SAD/MAD Study in Healthy Subjects
NCT06997484Phase 1Recruiting
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing HL-400 with Placebo (2 arms). Primary endpoints: Number and percentage of participants with adverse events, Number and percentage of adverse events according to severity and 7 more. Started Apr 2025; status: recruiting.
02
Drugs
HL-400
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06997484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997484.